(Q38099726)

English

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

scientific article published on 15 April 2013

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Florian Lordick

1

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Yoon-Koo Kang

2

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Hyun-Cheol Chung

3

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Pamela Salman

4

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Sang Cheul Oh

5

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

György Bodoky

6

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Galina Kurteva

7

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Constantin Volovat

8

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Vladimir M Moiseyenko

9

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Vera Gorbunova

10

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Joon Oh Park

11

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Akira Sawaki

12

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Ilhan Celik

13

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Heiko Götte

14

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Helena Melezínková

15

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Markus Moehler

16

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators

17

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

15 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

490-499

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of advanced gastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy for advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR and cancer prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(13)70102-5

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38099726&oldid=1741162172"